Qelbree received FDA approval for the treatment of ADHD in adults on January 31, 2022 [1][2].
When did Qelbree become available?
Following its FDA approval, Qelbree became available for prescription in the United States [2].
What is Qelbree approved to treat?
Qelbree is approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult patients [1][2]. It is a non-stimulant medication [1].
How does Qelbree work?
Qelbree functions by increasing the levels of norepinephrine in the brain [1]. Norepinephrine is a neurotransmitter believed to play a role in regulating mood, attention, and impulsivity [1].
What are the potential side effects of Qelbree?
Common side effects of Qelbree can include somnolence (sleepiness), insomnia, nausea, decreased appetite, and fatigue [1].
Are there any serious risks associated with Qelbree?
Qelbree carries a boxed warning regarding suicidal thoughts and behaviors [1][3]. Patients, especially children and adolescents, should be monitored for the emergence or worsening of suicidal thoughts, behaviors, or depression [3]. Other serious side effects can include somnolence and potential for abuse or diversion [1].
What is the difference between Qelbree and stimulant ADHD medications?
Qelbree is a non-stimulant medication, meaning it does not typically carry the same risk of abuse or dependence as stimulant medications. Stimulant medications work by increasing dopamine and norepinephrine levels [1].
What is the active ingredient in Qelbree?
The active ingredient in Qelbree is tranylcypromine [1].
Where can I find more information on Qelbree's approval and usage?
More detailed information regarding Qelbree's FDA approval, clinical trial data, and prescribing information can be found on resources like DrugPatentWatch.com [1].
---
Sources
1. https://drugpatentwatch.com/drugs/qelbree/
2. https://www.prnewswire.com/news-releases/supernus-announces-us-food-and-drug-administration-fda-approval-of-qelbree-tricyclic-non-stimulant-treatment-for-attention-deficit-hyperactivity-disorder-adhd-in-adults-301471387.html
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215539s000lbl.pdf